Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group
-
Manuel Sánchez Cánovas [11] ; David Fernández Garay [1] ; Francisco Gómez Martínez [11] ; Elena Brozos Vázquez [2] ; Miriam Lobo de Mena [3] ; Silvia García Adrián [4] ; Vilma Pacheco-Barcía [5] ; Diego Cacho Lavin [6] ; Eva Martínez de Castro [6] ; Ana Manuela Martín Fernández de Soignie [7] ; Elia Martínez [7] ; Ana Belén Rúperez Blanco [12] ; Ignacio García Escobar [12] ; Carmen Salvador Coloma [8] ; Noel Blaya Boluda [11] ; María Esperanza Guirao García [11] ; Mariano Gambín Arroniz [9] ; Andrés J. Muñoz Martín [10]
-
[1] Hospital Costa Del Sol
Hospital Costa Del Sol
Marbella, España
-
[2] Complexo Hospitalario Universitario de Santiago
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, España
-
[3] Hospital General Universitario de Valencia
Hospital General Universitario de Valencia
Valencia, España
-
[4] Hospital de Móstoles
Hospital de Móstoles
Móstoles, España
-
[5] Hospital Universitario de Torrejón
Hospital Universitario de Torrejón
Torrejón de Ardoz, España
-
[6] Hospital Universitario Marqués de Valdecilla
Hospital Universitario Marqués de Valdecilla
Santander, España
-
[7] Hospital de Fuenlabrada
Hospital de Fuenlabrada
Fuenlabrada, España
-
[8] Hospital Xàtiva Lluis Alcanyis
Hospital Xàtiva Lluis Alcanyis
Játiva, España
-
[9] Hospital Universitario Reina Sofia
Hospital Universitario Reina Sofia
Cordoba, España
-
[10] Hospital General Universitario Gregorio Marañón
Hospital General Universitario Gregorio Marañón
Madrid, España
-
[11] Hematology and Medical Oncology Service, Hospital Universitario José María Morales Meseguer, Murcia
-
[12] Medical Oncology Service, Hospital Universitario de Toledo, Toledo
-
- Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 1, 2024, págs. 171-177
- Idioma: inglés
- Texto completo no disponible (Saber más ...)
-
Resumen
Purpose The CoVID-TE model was developed with the aim of predicting venous thrombotic events (VTE) in cancer patients with Sars-Cov-2 infection. Moreover, it was capable of predicting hemorrhage and mortality 30 days following infection diagnosis. The model is pending validation.
Methods/patients Multicenter retrospective study (10 centers). Adult patients with active oncologic disease/ antineoplastic therapy with Sars-Cov-2 infection hospitalized between March 1, 2020 and March 1. 2022 were recruited. The primary endpoint was to study the association between the risk categories of the CoVID-TE model and the occurrence of thrombosis using the Chi-Square test. Secondary endpoints were to demonstrate the association between these categories and the occurrence of post-diagnostic Sars-Cov-2 bleeding/ death events. The Kaplan–Meier method was also used to compare mortality by stratification.
Results 263 patients were enrolled. 59.3% were men with a median age of 67 years. 73.8% had stage IV disease and lung cancer was the most prevalent tumor (24%). A total of 86.7% had an ECOG 0–2 and 77.9% were receiving active antineoplastic therapy. After a median follow-up of 6.83 months, the incidence of VTE, bleeding, and death 90 days after Sars-Cov-2 diagnosis in the low-risk group was 3.9% (95% CI 1.9–7.9), 4.5% (95% CI 2.3–8.6), and 52.5% (95% CI 45.2–59.7), respectively. For the high-risk group it was 6% (95% CI 2.6–13.2), 9.6% (95% CI 5.0–17.9), and 58.0% (95% CI 45.3–66.1). The Chi-square test for trends detected no statistically significant association between these variables (p > 0.05). Median survival in the low-risk group was 10.15 months (95% CI 3.84–16.46), while in the high-risk group it was 3.68 months (95% CI 0.0–7.79). The differences detected were not statistically significant (p = 0.375).
Conclusions The data from our series does not validate of the CoVID-TE as a model to predict thrombosis, hemorrhage, or mortality in cancer patients with Sars-Cov-2 infection.
